Skip to main content
    C

    Cyclerion Therapeutics Inc (CYCN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.36
    -0.89 (-20.94%)

    Market Cap: $15.73M

    Last updated: Sep 08, 2026 at 7:42 PM ET

    Cyclerion Therapeutics Inc (CYCN) Financials: Revenue, Profit and Cash Flow

    Updated Aug 4, 2026. Financial statements from company filings, amounts in US dollars.

    Cyclerion Therapeutics reported revenue of $2.07M for the fiscal year ended Dec 31, 2025, up 3.7% from the year before. That year, net income was -$3.53M with a net margin of -170.1%, operating cash flow was -$3.31M and free cash flow was -$3.31M. The quarter ended Jun 30, 2026 had revenue of $0 and net income of -$1.75M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue fell from $4.51M, a compound annual decline of 12.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$2.07M+3.7%100.0%-239.8%-170.1%
    Dec 2024$2.00MN/A100.0%-181.4%-152.8%
    Dec 2023$0-100.0%N/AN/AN/A
    Dec 2022$297.00K-92.5%100.0%-6242.4%-14841.1%
    Dec 2021$3.94M+71.7%100.0%-1400.2%-1310.2%
    Dec 2020$2.30M-49.1%100.0%-3539.4%-3388.6%
    Dec 2019$4.51MN/A100.0%-2774.3%-2729.3%
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$2.07M$2.00M$0$297.00K$3.94M$2.30M$4.51M$0$0$0
    Cost of revenue$0$0$0$0$0$0$0$0$1.75M$2.17M
    Gross profit$2.07M$2.00M$0$297.00K$3.94M$2.30M$4.51M$0-$1.75M-$2.17M
    Research and development$959.00K$286.00K$1.51M$5.98M$37.64M$56.41M$95.14M$87.72M$78.80M$50.90M
    Operating income-$4.97M-$3.63M-$12.95M-$18.54M-$55.20M-$81.27M-$125.04M-$115.25M-$93.92M-$63.55M
    Net income-$3.53M-$3.06M-$5.26M-$44.08M-$51.65M-$77.80M-$123.01M-$115.25M-$93.92M-$63.55M
    EBITDA-$3.53M-$3.06M-$12.59M-$18.48M-$54.72M-$78.97M-$122.34M-$113.72M-$92.18M-$61.38M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Revenue$0$0$1.20M$875.00K$93.00K$81.00K$1.81M$194.00K$0$0$0$0
    Gross profit$0$0$1.20M$875.00K$93.00K$81.00K$1.81M$194.00K$0$0N/A$0
    Operating income-$1.77M-$3.21M-$838.00K-$1.01M-$1.67M-$1.46M$502.00K-$1.13M-$1.38M-$1.62M-$1.80M-$6.01M
    Net income-$1.75M-$3.18M-$799.00K-$976.00K-$324.00K-$1.43M$530.00K-$723.00K-$1.32M-$1.54M-$1.69M$7.57M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $3.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$9.98M$9.57M$13.37M$18.08M$59.33M$115.38M$186.48M$7.40M$5.47M$3.88M
    Current assets$4.63M$4.22M$8.02M$14.82M$55.46M$58.50M$101.20M$879.00K$1.26M$275.00K
    Cash and equivalents$3.24M$3.23M$7.57M$13.38M$53.96M$54.40M$94.89M$0$0$0
    Total liabilities$900.00K$725.00K$2.09M$7.63M$11.09M$55.88M$88.75M$17.85M$14.04M$10.64M
    Short-term debt$0N/AN/AN/AN/A$3.51M$0$0$0$0
    Shareholder equity$9.09M$8.85M$11.29M$10.45M$48.25M$59.49M$97.73M-$10.45M-$8.57M-$6.76M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total assets$6.93M$8.51M$9.98M$10.41M$9.37M$9.85M$9.57M$8.90M$10.06M$11.36M$13.37M$15.21M
    Total liabilities$1.84M$1.71M$900.00K$877.00K$800.00K$1.07M$725.00K$700.00K$1.28M$1.44M$2.09M$2.34M
    Cash and equivalents$1.39M$2.82M$3.24M$4.57M$3.01M$3.64M$3.23M$2.87M$4.59M$5.70M$7.57M$9.11M
    Shareholder equity$5.09M$6.79M$9.09M$9.54M$8.57M$8.78M$8.85M$8.20M$8.78M$9.92M$11.29M$12.87M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$3.31M-$4.33M-$21.25M-$40.61M-$36.52M-$72.49M-$102.22M-$97.50M-$81.22M-$49.87M
    Capital expenditures$0$0$0$0$7.00K$1.52M$6.89M$3.44M$1.40M$1.45M
    Free cash flow-$3.31M-$4.33M-$21.25M-$40.61M-$36.52M-$74.01M-$109.10M-$100.94M-$82.62M-$51.32M
    Share repurchasesN/AN/AN/AN/AN/A$0$10.38M$0N/AN/A
    Investing cash flow$0$0$10.40M$0$1.46M$18.00K-$6.71M-$3.44M-$1.40M-$1.45M
    Financing cash flow$3.32M$0$5.02M$29.00K$30.79M$28.09M$211.57M$100.94M$82.62M$51.32M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Operating cash flow-$1.43M-$1.18M-$1.58M-$264.00K-$503.00K-$968.00K$360.00K-$1.72M-$1.11M-$1.87M-$1.54M-$6.93M
    Capital expendituresN/A$66.00K$0$0$0$0$0$0$0$0$0$0
    Free cash flowN/A-$1.24M-$1.58M-$264.00K-$503.00K-$968.00K$360.00K-$1.72M-$1.11M-$1.87M-$1.54M-$6.93M
    Last 12 quarters

    Frequently Asked Questions About CYCN

    What is Cyclerion Therapeutics' annual revenue?

    Cyclerion Therapeutics reported revenue of $2.07M for the fiscal year ended Dec 31, 2025.

    How fast is Cyclerion Therapeutics' revenue growing?

    Revenue was up 3.7% for the fiscal year ended Dec 31, 2025 compared with the year before.

    Is Cyclerion Therapeutics profitable?

    No. Cyclerion Therapeutics reported net income of -$3.53M for the fiscal year ended Dec 31, 2025, with a net margin of -170.1%.

    How much free cash flow does CYCN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$3.31M minus capital expenditures of $0 produced free cash flow of -$3.31M.

    How much debt does Cyclerion Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $3.24M.